Adoram Therapeutics is a company that uses the benefits of allosteric biochemistry to develop novel therapies.
Adoram Therapeutics has raised $1.3M in total funding. The most recent round was Grant. The last funding was announced in May 2025.
Adoram Therapeutics's investors include Innosuisse, FONGIT Innovation Fund, Ipalmetrix.
Adoram Therapeutics is headquartered in Swiss, United States.
Adoram Therapeutics is a company that uses the benefits of allosteric biochemistry to develop novel therapies.
Adoram Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Adoram Therapeutics — Funding & Investors." VCBacked, May 5, 2025, https://www.vcbacked.co/company/adoram-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Adoram Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/adoram-therapeutics
{{cite web |title=Adoram Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adoram-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated